Who to call at Andelyn Biosciences, and when
Fundz watches for the moments Andelyn Biosciences starts buying, and tells you who to reach.
- An alert the day Andelyn Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Andelyn Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Andelyn Biosciences. With Fundz connected, it knows.
Andelyn Biosciences Partners with Celliaz to Develop Gene Therapy CLZ002 for Retinitis Pigmentosa.
Contract Type
partnership
Description
Andelyn Biosciences has formed a strategic partnership with Celliaz Co., Ltd. to develop CLZ002, an investigational gene therapy targeting retinitis pigmentosa. This gene-agnostic therapy aims to address the unmet need for effective treatments in retinal diseases.
Quick answer
Andelyn Biosciences Partners with Celliaz to Develop Gene Therapy CLZ002 for Retinitis Pigmentosa. (November 12, 2026). Andelyn Biosciences is based in Columbus, Ohio, United States.
- What agreement did Andelyn Biosciences announce on November 12, 2026?
- Andelyn Biosciences has formed a strategic partnership with Celliaz Co., Ltd. to develop CLZ002, an investigational gene therapy targeting retinitis pigmentosa. This gene-agnostic therapy aims to address the unmet need for effective treatments in retinal diseases.
- What does Andelyn Biosciences do?
- Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy.
- Where is Andelyn Biosciences based?
- Andelyn Biosciences is based in Columbus, Ohio, United States.
- Which similar companies announced agreements around the same time?
- Sino Biopharmaceutical (November 13, 2026), OXB (November 17, 2026), Teva Pharmaceutical Industries Ltd (November 3, 2026) and AbbVie Inc. (November 3, 2026) also announced agreements within 45 days of Andelyn Biosciences.
Source: Fundz verified event record.
Other recent agreements in Therapeutics and Manufacturing
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Sino Biopharmaceutical Partners with Boehringer Ingelheim in a $358 Million Oncology Deal (November 13, 2026)
- OXB and Aura Biosciences form partnership to support Phase 3 development of oncology candidate. (November 17, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Rhode Island Life Science Hub and Cognito Therapeutics launch partnership for Alzheimer's research. (October 27, 2026)
- Celltrion Secures Exclusive Supply Agreement for Omlyclo and Aptozma with U.S. Healthcare Company to Expand Market Access. (October 26, 2026)
Related People
Agreement Insights
What this usually meansAndelyn Biosciences signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.